| א' | ב' | ג' | ד' | ה' | ו' | ש' |
|---|---|---|---|---|---|---|
|
27 |
28 |
29 |
30 |
2 |
3 |
|
|
|
|
|
|
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
|
|
|
|
4 |
5 |
6
|
7 |
8 |
9
|
10 |
|
|
|
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
|
|
|
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
|
|
|
11 |
12 |
13 |
14 |
15 |
17 |
|
|
|
|
|
|
|
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
|
|
|
18 |
20
|
21 |
22 |
23 |
24 |
|
|
|
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
|
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)
National Institute of Neurological Disorders and Stroke/NIH
|
|
|
|
|
|
25 |
26 |
27 |
28 |
29 |
30 |
31 |
|
|
|
|
|
|
|
|
